Amanda Nickles Fader, MD

Bogani G et al. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis. Gynecol Oncol 2016;143(2):443-7. Abstract

George S et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer 2014;120(5):738-43. Abstract

Hensley ML et al. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study. Proc ASCO 2018;Abstract 5505.

Hensley ML et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: Results of a phase 2 trial (SARC 005). Cancer 2013;119(8):1555-61. Abstract

Hensley ML et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol 2009;112(3):563-7. Abstract

Kapp DS et al. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008;112(4):820-30. Abstract

Omura GA et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: A Gynecologic Oncology Group study. J Clin Oncol 1985;3(9):1240-5. Abstract

Pautier P et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol 2013;24(4):1099-104. Abstract

Reed NS et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer 2008;44(6):808-18. Abstract

Ricci S et al. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol 2013;131(3):629-33. Abstract

Brian A Van Tine, MD, PhD

Cote GM et al. Next-generation sequencing for patients with sarcoma: A single center experience. Oncologist 2018;23(2):234-42. Abstract

Demetri GD et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016;34(8):786-93. Abstract

Demetri GD et al. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). Proc ASCO 2015;Abstract 10503.

Seddon B et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial. Lancet Oncol 2017;18(10):1397-410. Abstract

Schoffski P et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387(10028):1629-37. Abstract

Tap WD et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial. Lancet 2016;38(10043):488-97. Abstract

Van der Graaf WT et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379(9829):1879-86. Abstract